@Article{,
AUTHOR = {Christopher H. Cantrill, Kevin C. Zorn, Dean S. Elterman, Ricardo R. Gonzalez},
TITLE = {The Rezum system – a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {26},
YEAR = {2019},
NUMBER = {3},
PAGES = {9787--9793},
URL = {http://www.techscience.com/CJU/v26n3/60648},
ISSN = {1488-5581},
ABSTRACT = {Benign prostatic hyperplasia (BPH) and accompanying 
lower urinary tract symptoms (LUTS) sits in the top ten 
prominent and costly disease conditions in men over 50 
years of age. In the United States it is the most common 
diagnosis made by urologists for men 45 to 74 years of age. 
Twenty percent of the population will reach 65 years of age 
or older by 2030, and those over 85 years will represent 
the fastest growing segment of our population. The 
prevalence of symptomatic BPH increases proportionally 
with the aging population. It is estimated that BPH now affects 6% of the male population worldwide. Moreover, 
in Canada, the estimated BPH prevalence is more than 
1 million men aged 50 years and older. Among the various 
surgical treatments, Rezum water vapor thermal therapy 
has been developed as a unique, rapid and reproducible 
minimally invasive surgical treatment exhibiting safe 
and early effective relief of LUTS/BPH. The targeted 
prostate tissue ablation is amenable to all zones of the 
prostate including intravesical median lobes. We present 
our experiences with this technique, which can be quickly 
performed under local anesthesia in an office setting.},
DOI = {}
}